Global Orphan Drugs Market Analysis By Segmentations, Top Key Players, Geographical Expansion, Future Development & Forecast 2024-2035
- PUBLISHED ON
- 1/12/2023
- NO OF PAGES
- 228
- CATEGORY
- Healthcare & Life Sciences
Orphan Drugs market report presents a global overview of market shares, size, statistics, trends, demand, revenue and growth opportunities by key players, regions and countries. This report offers a complete market overview during the past, present, and the forecast period till 2032 which helps to identify future opportunities, risk factors, growing areas. Report also highlight on recent developments, technological innovations, market affecting factors, demographics analysis, demand and supply chain which gives brief strategy of market growth during the forecast period. It also gives in-depth insights on SWOT and PESTLE analysis based on industry segmentations and regional developments.
Market Overview:
The report provides a basic overview of the industry including definitions, classifications, and industry chain structure. The Orphan Drugs market analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status. Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed. This report also states import/export consumption, supply and demand, price, revenue and gross margins.
Report Scope:
The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Orphan Drugs manufacturers, distributors, end users, industry associations, governments’ industry bureaus, industry publications, industry experts, third party database, and our in-house databases. The report combines extensive quantitative analysis and exhaustive qualitative analysis, ranges from a macro overview of the total market size, industry chain, and market dynamics to micro details of segment by type, application and region and as a result provides a holistic view of as well as a deep insight into the Orphan Drugs market covering all its essential aspects.
Global Orphan Drugs Market: Segmentations
Global Orphan Drugs Market: By Key Players
Novartis AG
Bristol-Myers Squibb Company
Celgene Corporation
F. Hoffmann-La Roche Ltd.
Pfizer, Inc.
Sanofi S.A.
Alexion Pharmaceuticals, Inc.
Eli Lilly and Company
Novo Nordisk A/S
AstraZeneca
Eisai Co., Ltd.
Daiichi Sankyo Company Limited
Bayer AG
GlaxoSmithKline
Merck & Co., Inc.
Johnson & Johnson
Biogen, Inc.
Takeda
Amgen, Inc.
Global Orphan Drugs Market: By Types
Oncology
Gastrointestinal
Pulmonary
Neurology
Hematology
Cardio-vascular
Metabolic disorders
Endocrinology
Infectious diseases
Global Orphan Drugs Market: By Applications
Hospital Pharmacies
Speciality Pharmacies
Retail pharmacies
Global Orphan Drugs Market: Regional Analysis
The countries covered in the regional analysis of the Global Orphan Drugs market report are U.S., Canada, and Mexico in North America, Germany, France, U.K., Russia, Italy, Spain, Turkey, Netherlands, Switzerland, Belgium, and Rest of Europe in Europe, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, China, Japan, India, South Korea, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), and Argentina, Brazil, and Rest of South America as part of South America.
Key Benefits:
• The analysis provides an overview of the factors driving and limiting the growth of the market including trends, structure and others.
• Market estimation for type and geographic segments is derived from the current market scenario and expected market trends.
• Porter’s Five Force Model and SWOT analysis are used to study the global Orphan Drugs market and would help stakeholders make strategic decisions.
• The analysis assists in understanding the strategies adopted by the companies for the growth of this market.
• In-depth analysis of the types of Orphan Drugs would help in identifying future applications in this market.
Reasons to Purchase this Report:
• Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors
• Provision of market value (USD Billion) data for each segment and sub-segment
• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
• Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
• The current as well as the future market outlook of the industry with respect to recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
• Includes in-depth analysis of the market of various perspectives through Porter’s five forces analysis
• Provides insight into the market through Value Chain
• Market dynamics scenario, along with growth opportunities of the market in the years to come
• 6-month post-sales analyst support
Objectives of the Study:
• To provide with an exhaustive analysis on the Orphan Drugs Market by Product, By Application, By End User and by Region.
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
• To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions
Base Year: 2023Market Overview:
The report provides a basic overview of the industry including definitions, classifications, and industry chain structure. The Orphan Drugs market analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status. Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed. This report also states import/export consumption, supply and demand, price, revenue and gross margins.
Report Scope:
The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Orphan Drugs manufacturers, distributors, end users, industry associations, governments’ industry bureaus, industry publications, industry experts, third party database, and our in-house databases. The report combines extensive quantitative analysis and exhaustive qualitative analysis, ranges from a macro overview of the total market size, industry chain, and market dynamics to micro details of segment by type, application and region and as a result provides a holistic view of as well as a deep insight into the Orphan Drugs market covering all its essential aspects.
Global Orphan Drugs Market: Segmentations
Global Orphan Drugs Market: By Key Players
Novartis AG
Bristol-Myers Squibb Company
Celgene Corporation
F. Hoffmann-La Roche Ltd.
Pfizer, Inc.
Sanofi S.A.
Alexion Pharmaceuticals, Inc.
Eli Lilly and Company
Novo Nordisk A/S
AstraZeneca
Eisai Co., Ltd.
Daiichi Sankyo Company Limited
Bayer AG
GlaxoSmithKline
Merck & Co., Inc.
Johnson & Johnson
Biogen, Inc.
Takeda
Amgen, Inc.
Global Orphan Drugs Market: By Types
Oncology
Gastrointestinal
Pulmonary
Neurology
Hematology
Cardio-vascular
Metabolic disorders
Endocrinology
Infectious diseases
Global Orphan Drugs Market: By Applications
Hospital Pharmacies
Speciality Pharmacies
Retail pharmacies
Global Orphan Drugs Market: Regional Analysis
The countries covered in the regional analysis of the Global Orphan Drugs market report are U.S., Canada, and Mexico in North America, Germany, France, U.K., Russia, Italy, Spain, Turkey, Netherlands, Switzerland, Belgium, and Rest of Europe in Europe, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, China, Japan, India, South Korea, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), and Argentina, Brazil, and Rest of South America as part of South America.
Key Benefits:
• The analysis provides an overview of the factors driving and limiting the growth of the market including trends, structure and others.
• Market estimation for type and geographic segments is derived from the current market scenario and expected market trends.
• Porter’s Five Force Model and SWOT analysis are used to study the global Orphan Drugs market and would help stakeholders make strategic decisions.
• The analysis assists in understanding the strategies adopted by the companies for the growth of this market.
• In-depth analysis of the types of Orphan Drugs would help in identifying future applications in this market.
Reasons to Purchase this Report:
• Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors
• Provision of market value (USD Billion) data for each segment and sub-segment
• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
• Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
• The current as well as the future market outlook of the industry with respect to recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
• Includes in-depth analysis of the market of various perspectives through Porter’s five forces analysis
• Provides insight into the market through Value Chain
• Market dynamics scenario, along with growth opportunities of the market in the years to come
• 6-month post-sales analyst support
Objectives of the Study:
• To provide with an exhaustive analysis on the Orphan Drugs Market by Product, By Application, By End User and by Region.
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
• To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions
Historic Year: 2016-2022
Forecast: 2024-2035
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Orphan Drugs Revenue
1.4 Market Analysis by Type
1.4.1 Global Orphan Drugs Market Size Growth Rate by Type: 2023 VS 2032
1.4.2 Oncology
1.4.3 Gastrointestinal
1.4.4 Pulmonary
1.4.5 Neurology
1.4.6 Hematology
1.4.7 Cardio-vascular
1.4.8 Metabolic disorders
1.4.9 Endocrinology
1.4.10 Infectious diseases
1.5 Market by Application
1.5.1 Global Orphan Drugs Market Share by Application: 2023-2032
1.5.2 Hospital Pharmacies
1.5.3 Speciality Pharmacies
1.5.4 Retail pharmacies
1.6 Study Objectives
1.7 Years Considered
1.8 Overview of Global Orphan Drugs Market
1.8.1 Global Orphan Drugs Market Status and Outlook (2017-2032)
1.8.2 North America
1.8.3 East Asia
1.8.4 Europe
1.8.5 South Asia
1.8.6 Southeast Asia
1.8.7 Middle East
1.8.8 Africa
1.8.9 Oceania
1.8.10 South America
1.8.11 Rest of the World
2 Market Competition by Manufacturers
2.1 Global Orphan Drugs Production Capacity Market Share by Manufacturers (2017-2022)
2.2 Global Orphan Drugs Revenue Market Share by Manufacturers (2017-2022)
2.3 Global Orphan Drugs Average Price by Manufacturers (2017-2022)
2.4 Manufacturers Orphan Drugs Production Sites, Area Served, Product Type
3 Sales by Region
3.1 Global Orphan Drugs Sales Volume Market Share by Region (2017-2022)
3.2 Global Orphan Drugs Sales Revenue Market Share by Region (2017-2022)
3.3 North America Orphan Drugs Sales Volume
3.3.1 North America Orphan Drugs Sales Volume Growth Rate (2017-2022)
3.3.2 North America Orphan Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2017-2022)
3.4 East Asia Orphan Drugs Sales Volume
3.4.1 East Asia Orphan Drugs Sales Volume Growth Rate (2017-2022)
3.4.2 East Asia Orphan Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2017-2022)
3.5 Europe Orphan Drugs Sales Volume (2017-2022)
3.5.1 Europe Orphan Drugs Sales Volume Growth Rate (2017-2022)
3.5.2 Europe Orphan Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2017-2022)
3.6 South Asia Orphan Drugs Sales Volume (2017-2022)
3.6.1 South Asia Orphan Drugs Sales Volume Growth Rate (2017-2022)
3.6.2 South Asia Orphan Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2017-2022)
3.7 Southeast Asia Orphan Drugs Sales Volume (2017-2022)
3.7.1 Southeast Asia Orphan Drugs Sales Volume Growth Rate (2017-2022)
3.7.2 Southeast Asia Orphan Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2017-2022)
3.8 Middle East Orphan Drugs Sales Volume (2017-2022)
3.8.1 Middle East Orphan Drugs Sales Volume Growth Rate (2017-2022)
3.8.2 Middle East Orphan Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2017-2022)
3.9 Africa Orphan Drugs Sales Volume (2017-2022)
3.9.1 Africa Orphan Drugs Sales Volume Growth Rate (2017-2022)
3.9.2 Africa Orphan Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2017-2022)
3.10 Oceania Orphan Drugs Sales Volume (2017-2022)
3.10.1 Oceania Orphan Drugs Sales Volume Growth Rate (2017-2022)
3.10.2 Oceania Orphan Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2017-2022)
3.11 South America Orphan Drugs Sales Volume (2017-2022)
3.11.1 South America Orphan Drugs Sales Volume Growth Rate (2017-2022)
3.11.2 South America Orphan Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2017-2022)
3.12 Rest of the World Orphan Drugs Sales Volume (2017-2022)
3.12.1 Rest of the World Orphan Drugs Sales Volume Growth Rate (2017-2022)
3.12.2 Rest of the World Orphan Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2017-2022)
4 North America
4.1 North America Orphan Drugs Consumption by Countries
4.2 United States
4.3 Canada
4.4 Mexico
5 East Asia
5.1 East Asia Orphan Drugs Consumption by Countries
5.2 China
5.3 Japan
5.4 South Korea
6 Europe
6.1 Europe Orphan Drugs Consumption by Countries
6.2 Germany
6.3 United Kingdom
6.4 France
6.5 Italy
6.6 Russia
6.7 Spain
6.8 Netherlands
6.9 Switzerland
6.10 Poland
7 South Asia
7.1 South Asia Orphan Drugs Consumption by Countries
7.2 India
7.3 Pakistan
7.4 Bangladesh
8 Southeast Asia
8.1 Southeast Asia Orphan Drugs Consumption by Countries
8.2 Indonesia
8.3 Thailand
8.4 Singapore
8.5 Malaysia
8.6 Philippines
8.7 Vietnam
8.8 Myanmar
9 Middle East
9.1 Middle East Orphan Drugs Consumption by Countries
9.2 Turkey
9.3 Saudi Arabia
9.4 Iran
9.5 United Arab Emirates
9.6 Israel
9.7 Iraq
9.8 Qatar
9.9 Kuwait
9.10 Oman
10 Africa
10.1 Africa Orphan Drugs Consumption by Countries
10.2 Nigeria
10.3 South Africa
10.4 Egypt
10.5 Algeria
10.6 Morocco
11 Oceania
11.1 Oceania Orphan Drugs Consumption by Countries
11.2 Australia
11.3 New Zealand
12 South America
12.1 South America Orphan Drugs Consumption by Countries
12.2 Brazil
12.3 Argentina
12.4 Columbia
12.5 Chile
12.6 Venezuela
12.7 Peru
12.8 Puerto Rico
12.9 Ecuador
13 Rest of the World
13.1 Rest of the World Orphan Drugs Consumption by Countries
13.2 Kazakhstan
14 Sales Volume, Sales Revenue, Sales Price Trend by Type
14.1 Global Orphan Drugs Sales Volume Market Share by Type (2017-2022)
14.2 Global Orphan Drugs Sales Revenue Market Share by Type (2017-2022)
14.3 Global Orphan Drugs Sales Price by Type (2017-2022)
15 Consumption Analysis by Application
15.1 Global Orphan Drugs Consumption Volume by Application (2017-2022)
15.2 Global Orphan Drugs Consumption Value by Application (2017-2022)
16 Company Profiles and Key Figures in Orphan Drugs Business
16.1 Novartis AG
16.1.1 Novartis AG Company Profile
16.1.2 Novartis AG Orphan Drugs Product Specification
16.1.3 Novartis AG Orphan Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
16.2 Bristol-Myers Squibb Company
16.2.1 Bristol-Myers Squibb Company Company Profile
16.2.2 Bristol-Myers Squibb Company Orphan Drugs Product Specification
16.2.3 Bristol-Myers Squibb Company Orphan Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
16.3 Celgene Corporation
16.3.1 Celgene Corporation Company Profile
16.3.2 Celgene Corporation Orphan Drugs Product Specification
16.3.3 Celgene Corporation Orphan Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
16.4 F. Hoffmann-La Roche Ltd.
16.4.1 F. Hoffmann-La Roche Ltd. Company Profile
16.4.2 F. Hoffmann-La Roche Ltd. Orphan Drugs Product Specification
16.4.3 F. Hoffmann-La Roche Ltd. Orphan Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
16.5 Pfizer, Inc.
16.5.1 Pfizer, Inc. Company Profile
16.5.2 Pfizer, Inc. Orphan Drugs Product Specification
16.5.3 Pfizer, Inc. Orphan Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
16.6 Sanofi S.A.
16.6.1 Sanofi S.A. Company Profile
16.6.2 Sanofi S.A. Orphan Drugs Product Specification
16.6.3 Sanofi S.A. Orphan Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
16.7 Alexion Pharmaceuticals, Inc.
16.7.1 Alexion Pharmaceuticals, Inc. Company Profile
16.7.2 Alexion Pharmaceuticals, Inc. Orphan Drugs Product Specification
16.7.3 Alexion Pharmaceuticals, Inc. Orphan Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
16.8 Eli Lilly and Company
16.8.1 Eli Lilly and Company Company Profile
16.8.2 Eli Lilly and Company Orphan Drugs Product Specification
16.8.3 Eli Lilly and Company Orphan Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
16.9 Novo Nordisk A/S
16.9.1 Novo Nordisk A/S Company Profile
16.9.2 Novo Nordisk A/S Orphan Drugs Product Specification
16.9.3 Novo Nordisk A/S Orphan Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
16.10 AstraZeneca
16.10.1 AstraZeneca Company Profile
16.10.2 AstraZeneca Orphan Drugs Product Specification
16.10.3 AstraZeneca Orphan Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
16.11 Eisai Co., Ltd.
16.11.1 Eisai Co., Ltd. Company Profile
16.11.2 Eisai Co., Ltd. Orphan Drugs Product Specification
16.11.3 Eisai Co., Ltd. Orphan Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
16.12 Daiichi Sankyo Company Limited
16.12.1 Daiichi Sankyo Company Limited Company Profile
16.12.2 Daiichi Sankyo Company Limited Orphan Drugs Product Specification
16.12.3 Daiichi Sankyo Company Limited Orphan Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
16.13 Bayer AG
16.13.1 Bayer AG Company Profile
16.13.2 Bayer AG Orphan Drugs Product Specification
16.13.3 Bayer AG Orphan Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
16.14 GlaxoSmithKline
16.14.1 GlaxoSmithKline Company Profile
16.14.2 GlaxoSmithKline Orphan Drugs Product Specification
16.14.3 GlaxoSmithKline Orphan Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
16.15 Merck & Co., Inc.
16.15.1 Merck & Co., Inc. Company Profile
16.15.2 Merck & Co., Inc. Orphan Drugs Product Specification
16.15.3 Merck & Co., Inc. Orphan Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
16.16 Johnson & Johnson
16.16.1 Johnson & Johnson Company Profile
16.16.2 Johnson & Johnson Orphan Drugs Product Specification
16.16.3 Johnson & Johnson Orphan Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
16.17 Biogen, Inc.
16.17.1 Biogen, Inc. Company Profile
16.17.2 Biogen, Inc. Orphan Drugs Product Specification
16.17.3 Biogen, Inc. Orphan Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
16.18 Takeda
16.18.1 Takeda Company Profile
16.18.2 Takeda Orphan Drugs Product Specification
16.18.3 Takeda Orphan Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
16.19 Amgen, Inc.
16.19.1 Amgen, Inc. Company Profile
16.19.2 Amgen, Inc. Orphan Drugs Product Specification
16.19.3 Amgen, Inc. Orphan Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
17 Orphan Drugs Manufacturing Cost Analysis
17.1 Orphan Drugs Key Raw Materials Analysis
17.1.1 Key Raw Materials
17.2 Proportion of Manufacturing Cost Structure
17.3 Manufacturing Process Analysis of Orphan Drugs
17.4 Orphan Drugs Industrial Chain Analysis
18 Marketing Channel, Distributors and Customers
18.1 Marketing Channel
18.2 Orphan Drugs Distributors List
18.3 Orphan Drugs Customers
19 Market Dynamics
19.1 Market Trends
19.2 Opportunities and Drivers
19.3 Challenges
19.4 Porter's Five Forces Analysis
20 Production and Supply Forecast
20.1 Global Forecasted Production of Orphan Drugs (2023-2032)
20.2 Global Forecasted Revenue of Orphan Drugs (2023-2032)
20.3 Global Forecasted Price of Orphan Drugs (2017-2032)
20.4 Global Forecasted Production of Orphan Drugs by Region (2023-2032)
20.4.1 North America Orphan Drugs Production, Revenue Forecast (2023-2032)
20.4.2 East Asia Orphan Drugs Production, Revenue Forecast (2023-2032)
20.4.3 Europe Orphan Drugs Production, Revenue Forecast (2023-2032)
20.4.4 South Asia Orphan Drugs Production, Revenue Forecast (2023-2032)
20.4.5 Southeast Asia Orphan Drugs Production, Revenue Forecast (2023-2032)
20.4.6 Middle East Orphan Drugs Production, Revenue Forecast (2023-2032)
20.4.7 Africa Orphan Drugs Production, Revenue Forecast (2023-2032)
20.4.8 Oceania Orphan Drugs Production, Revenue Forecast (2023-2032)
20.4.9 South America Orphan Drugs Production, Revenue Forecast (2023-2032)
20.4.10 Rest of the World Orphan Drugs Production, Revenue Forecast (2023-2032)
20.5 Forecast by Type and by Application (2023-2032)
20.5.1 Global Sales Volume, Sales Revenue and Sales Price Forecast by Type (2023-2032)
20.5.2 Global Forecasted Consumption of Orphan Drugs by Application (2023-2032)
21 Consumption and Demand Forecast
21.1 North America Forecasted Consumption of Orphan Drugs by Country
21.2 East Asia Market Forecasted Consumption of Orphan Drugs by Country
21.3 Europe Market Forecasted Consumption of Orphan Drugs by Countriy
21.4 South Asia Forecasted Consumption of Orphan Drugs by Country
21.5 Southeast Asia Forecasted Consumption of Orphan Drugs by Country
21.6 Middle East Forecasted Consumption of Orphan Drugs by Country
21.7 Africa Forecasted Consumption of Orphan Drugs by Country
21.8 Oceania Forecasted Consumption of Orphan Drugs by Country
21.9 South America Forecasted Consumption of Orphan Drugs by Country
21.10 Rest of the world Forecasted Consumption of Orphan Drugs by Country
22 Research Findings and Conclusion
23 Methodology and Data Source
23.1 Methodology/Research Approach
23.1.1 Research Programs/Design
23.1.2 Market Size Estimation
23.1.3 Market Breakdown and Data Triangulation
23.2 Data Source
23.2.1 Secondary Sources
23.2.2 Primary Sources
23.3 Disclaimer
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Orphan Drugs Revenue
1.4 Market Analysis by Type
1.4.1 Global Orphan Drugs Market Size Growth Rate by Type: 2023 VS 2032
1.4.2 Oncology
1.4.3 Gastrointestinal
1.4.4 Pulmonary
1.4.5 Neurology
1.4.6 Hematology
1.4.7 Cardio-vascular
1.4.8 Metabolic disorders
1.4.9 Endocrinology
1.4.10 Infectious diseases
1.5 Market by Application
1.5.1 Global Orphan Drugs Market Share by Application: 2023-2032
1.5.2 Hospital Pharmacies
1.5.3 Speciality Pharmacies
1.5.4 Retail pharmacies
1.6 Study Objectives
1.7 Years Considered
1.8 Overview of Global Orphan Drugs Market
1.8.1 Global Orphan Drugs Market Status and Outlook (2017-2032)
1.8.2 North America
1.8.3 East Asia
1.8.4 Europe
1.8.5 South Asia
1.8.6 Southeast Asia
1.8.7 Middle East
1.8.8 Africa
1.8.9 Oceania
1.8.10 South America
1.8.11 Rest of the World
2 Market Competition by Manufacturers
2.1 Global Orphan Drugs Production Capacity Market Share by Manufacturers (2017-2022)
2.2 Global Orphan Drugs Revenue Market Share by Manufacturers (2017-2022)
2.3 Global Orphan Drugs Average Price by Manufacturers (2017-2022)
2.4 Manufacturers Orphan Drugs Production Sites, Area Served, Product Type
3 Sales by Region
3.1 Global Orphan Drugs Sales Volume Market Share by Region (2017-2022)
3.2 Global Orphan Drugs Sales Revenue Market Share by Region (2017-2022)
3.3 North America Orphan Drugs Sales Volume
3.3.1 North America Orphan Drugs Sales Volume Growth Rate (2017-2022)
3.3.2 North America Orphan Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2017-2022)
3.4 East Asia Orphan Drugs Sales Volume
3.4.1 East Asia Orphan Drugs Sales Volume Growth Rate (2017-2022)
3.4.2 East Asia Orphan Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2017-2022)
3.5 Europe Orphan Drugs Sales Volume (2017-2022)
3.5.1 Europe Orphan Drugs Sales Volume Growth Rate (2017-2022)
3.5.2 Europe Orphan Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2017-2022)
3.6 South Asia Orphan Drugs Sales Volume (2017-2022)
3.6.1 South Asia Orphan Drugs Sales Volume Growth Rate (2017-2022)
3.6.2 South Asia Orphan Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2017-2022)
3.7 Southeast Asia Orphan Drugs Sales Volume (2017-2022)
3.7.1 Southeast Asia Orphan Drugs Sales Volume Growth Rate (2017-2022)
3.7.2 Southeast Asia Orphan Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2017-2022)
3.8 Middle East Orphan Drugs Sales Volume (2017-2022)
3.8.1 Middle East Orphan Drugs Sales Volume Growth Rate (2017-2022)
3.8.2 Middle East Orphan Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2017-2022)
3.9 Africa Orphan Drugs Sales Volume (2017-2022)
3.9.1 Africa Orphan Drugs Sales Volume Growth Rate (2017-2022)
3.9.2 Africa Orphan Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2017-2022)
3.10 Oceania Orphan Drugs Sales Volume (2017-2022)
3.10.1 Oceania Orphan Drugs Sales Volume Growth Rate (2017-2022)
3.10.2 Oceania Orphan Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2017-2022)
3.11 South America Orphan Drugs Sales Volume (2017-2022)
3.11.1 South America Orphan Drugs Sales Volume Growth Rate (2017-2022)
3.11.2 South America Orphan Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2017-2022)
3.12 Rest of the World Orphan Drugs Sales Volume (2017-2022)
3.12.1 Rest of the World Orphan Drugs Sales Volume Growth Rate (2017-2022)
3.12.2 Rest of the World Orphan Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2017-2022)
4 North America
4.1 North America Orphan Drugs Consumption by Countries
4.2 United States
4.3 Canada
4.4 Mexico
5 East Asia
5.1 East Asia Orphan Drugs Consumption by Countries
5.2 China
5.3 Japan
5.4 South Korea
6 Europe
6.1 Europe Orphan Drugs Consumption by Countries
6.2 Germany
6.3 United Kingdom
6.4 France
6.5 Italy
6.6 Russia
6.7 Spain
6.8 Netherlands
6.9 Switzerland
6.10 Poland
7 South Asia
7.1 South Asia Orphan Drugs Consumption by Countries
7.2 India
7.3 Pakistan
7.4 Bangladesh
8 Southeast Asia
8.1 Southeast Asia Orphan Drugs Consumption by Countries
8.2 Indonesia
8.3 Thailand
8.4 Singapore
8.5 Malaysia
8.6 Philippines
8.7 Vietnam
8.8 Myanmar
9 Middle East
9.1 Middle East Orphan Drugs Consumption by Countries
9.2 Turkey
9.3 Saudi Arabia
9.4 Iran
9.5 United Arab Emirates
9.6 Israel
9.7 Iraq
9.8 Qatar
9.9 Kuwait
9.10 Oman
10 Africa
10.1 Africa Orphan Drugs Consumption by Countries
10.2 Nigeria
10.3 South Africa
10.4 Egypt
10.5 Algeria
10.6 Morocco
11 Oceania
11.1 Oceania Orphan Drugs Consumption by Countries
11.2 Australia
11.3 New Zealand
12 South America
12.1 South America Orphan Drugs Consumption by Countries
12.2 Brazil
12.3 Argentina
12.4 Columbia
12.5 Chile
12.6 Venezuela
12.7 Peru
12.8 Puerto Rico
12.9 Ecuador
13 Rest of the World
13.1 Rest of the World Orphan Drugs Consumption by Countries
13.2 Kazakhstan
14 Sales Volume, Sales Revenue, Sales Price Trend by Type
14.1 Global Orphan Drugs Sales Volume Market Share by Type (2017-2022)
14.2 Global Orphan Drugs Sales Revenue Market Share by Type (2017-2022)
14.3 Global Orphan Drugs Sales Price by Type (2017-2022)
15 Consumption Analysis by Application
15.1 Global Orphan Drugs Consumption Volume by Application (2017-2022)
15.2 Global Orphan Drugs Consumption Value by Application (2017-2022)
16 Company Profiles and Key Figures in Orphan Drugs Business
16.1 Novartis AG
16.1.1 Novartis AG Company Profile
16.1.2 Novartis AG Orphan Drugs Product Specification
16.1.3 Novartis AG Orphan Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
16.2 Bristol-Myers Squibb Company
16.2.1 Bristol-Myers Squibb Company Company Profile
16.2.2 Bristol-Myers Squibb Company Orphan Drugs Product Specification
16.2.3 Bristol-Myers Squibb Company Orphan Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
16.3 Celgene Corporation
16.3.1 Celgene Corporation Company Profile
16.3.2 Celgene Corporation Orphan Drugs Product Specification
16.3.3 Celgene Corporation Orphan Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
16.4 F. Hoffmann-La Roche Ltd.
16.4.1 F. Hoffmann-La Roche Ltd. Company Profile
16.4.2 F. Hoffmann-La Roche Ltd. Orphan Drugs Product Specification
16.4.3 F. Hoffmann-La Roche Ltd. Orphan Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
16.5 Pfizer, Inc.
16.5.1 Pfizer, Inc. Company Profile
16.5.2 Pfizer, Inc. Orphan Drugs Product Specification
16.5.3 Pfizer, Inc. Orphan Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
16.6 Sanofi S.A.
16.6.1 Sanofi S.A. Company Profile
16.6.2 Sanofi S.A. Orphan Drugs Product Specification
16.6.3 Sanofi S.A. Orphan Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
16.7 Alexion Pharmaceuticals, Inc.
16.7.1 Alexion Pharmaceuticals, Inc. Company Profile
16.7.2 Alexion Pharmaceuticals, Inc. Orphan Drugs Product Specification
16.7.3 Alexion Pharmaceuticals, Inc. Orphan Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
16.8 Eli Lilly and Company
16.8.1 Eli Lilly and Company Company Profile
16.8.2 Eli Lilly and Company Orphan Drugs Product Specification
16.8.3 Eli Lilly and Company Orphan Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
16.9 Novo Nordisk A/S
16.9.1 Novo Nordisk A/S Company Profile
16.9.2 Novo Nordisk A/S Orphan Drugs Product Specification
16.9.3 Novo Nordisk A/S Orphan Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
16.10 AstraZeneca
16.10.1 AstraZeneca Company Profile
16.10.2 AstraZeneca Orphan Drugs Product Specification
16.10.3 AstraZeneca Orphan Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
16.11 Eisai Co., Ltd.
16.11.1 Eisai Co., Ltd. Company Profile
16.11.2 Eisai Co., Ltd. Orphan Drugs Product Specification
16.11.3 Eisai Co., Ltd. Orphan Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
16.12 Daiichi Sankyo Company Limited
16.12.1 Daiichi Sankyo Company Limited Company Profile
16.12.2 Daiichi Sankyo Company Limited Orphan Drugs Product Specification
16.12.3 Daiichi Sankyo Company Limited Orphan Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
16.13 Bayer AG
16.13.1 Bayer AG Company Profile
16.13.2 Bayer AG Orphan Drugs Product Specification
16.13.3 Bayer AG Orphan Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
16.14 GlaxoSmithKline
16.14.1 GlaxoSmithKline Company Profile
16.14.2 GlaxoSmithKline Orphan Drugs Product Specification
16.14.3 GlaxoSmithKline Orphan Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
16.15 Merck & Co., Inc.
16.15.1 Merck & Co., Inc. Company Profile
16.15.2 Merck & Co., Inc. Orphan Drugs Product Specification
16.15.3 Merck & Co., Inc. Orphan Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
16.16 Johnson & Johnson
16.16.1 Johnson & Johnson Company Profile
16.16.2 Johnson & Johnson Orphan Drugs Product Specification
16.16.3 Johnson & Johnson Orphan Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
16.17 Biogen, Inc.
16.17.1 Biogen, Inc. Company Profile
16.17.2 Biogen, Inc. Orphan Drugs Product Specification
16.17.3 Biogen, Inc. Orphan Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
16.18 Takeda
16.18.1 Takeda Company Profile
16.18.2 Takeda Orphan Drugs Product Specification
16.18.3 Takeda Orphan Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
16.19 Amgen, Inc.
16.19.1 Amgen, Inc. Company Profile
16.19.2 Amgen, Inc. Orphan Drugs Product Specification
16.19.3 Amgen, Inc. Orphan Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
17 Orphan Drugs Manufacturing Cost Analysis
17.1 Orphan Drugs Key Raw Materials Analysis
17.1.1 Key Raw Materials
17.2 Proportion of Manufacturing Cost Structure
17.3 Manufacturing Process Analysis of Orphan Drugs
17.4 Orphan Drugs Industrial Chain Analysis
18 Marketing Channel, Distributors and Customers
18.1 Marketing Channel
18.2 Orphan Drugs Distributors List
18.3 Orphan Drugs Customers
19 Market Dynamics
19.1 Market Trends
19.2 Opportunities and Drivers
19.3 Challenges
19.4 Porter's Five Forces Analysis
20 Production and Supply Forecast
20.1 Global Forecasted Production of Orphan Drugs (2023-2032)
20.2 Global Forecasted Revenue of Orphan Drugs (2023-2032)
20.3 Global Forecasted Price of Orphan Drugs (2017-2032)
20.4 Global Forecasted Production of Orphan Drugs by Region (2023-2032)
20.4.1 North America Orphan Drugs Production, Revenue Forecast (2023-2032)
20.4.2 East Asia Orphan Drugs Production, Revenue Forecast (2023-2032)
20.4.3 Europe Orphan Drugs Production, Revenue Forecast (2023-2032)
20.4.4 South Asia Orphan Drugs Production, Revenue Forecast (2023-2032)
20.4.5 Southeast Asia Orphan Drugs Production, Revenue Forecast (2023-2032)
20.4.6 Middle East Orphan Drugs Production, Revenue Forecast (2023-2032)
20.4.7 Africa Orphan Drugs Production, Revenue Forecast (2023-2032)
20.4.8 Oceania Orphan Drugs Production, Revenue Forecast (2023-2032)
20.4.9 South America Orphan Drugs Production, Revenue Forecast (2023-2032)
20.4.10 Rest of the World Orphan Drugs Production, Revenue Forecast (2023-2032)
20.5 Forecast by Type and by Application (2023-2032)
20.5.1 Global Sales Volume, Sales Revenue and Sales Price Forecast by Type (2023-2032)
20.5.2 Global Forecasted Consumption of Orphan Drugs by Application (2023-2032)
21 Consumption and Demand Forecast
21.1 North America Forecasted Consumption of Orphan Drugs by Country
21.2 East Asia Market Forecasted Consumption of Orphan Drugs by Country
21.3 Europe Market Forecasted Consumption of Orphan Drugs by Countriy
21.4 South Asia Forecasted Consumption of Orphan Drugs by Country
21.5 Southeast Asia Forecasted Consumption of Orphan Drugs by Country
21.6 Middle East Forecasted Consumption of Orphan Drugs by Country
21.7 Africa Forecasted Consumption of Orphan Drugs by Country
21.8 Oceania Forecasted Consumption of Orphan Drugs by Country
21.9 South America Forecasted Consumption of Orphan Drugs by Country
21.10 Rest of the world Forecasted Consumption of Orphan Drugs by Country
22 Research Findings and Conclusion
23 Methodology and Data Source
23.1 Methodology/Research Approach
23.1.1 Research Programs/Design
23.1.2 Market Size Estimation
23.1.3 Market Breakdown and Data Triangulation
23.2 Data Source
23.2.1 Secondary Sources
23.2.2 Primary Sources
23.3 Disclaimer
Quality Assurance Process
- We Market Research’s Quality Assurance program strives to deliver superior value to our clients.
We Market Research senior executive is assigned to each consulting engagement and works closely with the project team to deliver as per the clients expectations.
Market Research Process
We Market Research monitors 3 important attributes during the QA process- Cost, Schedule & Quality. We believe them as a critical benchmark in achieving a project’s success.
To mitigate risks that can impact project success, we deploy the follow project delivery best practices:
- Project kickoff meeting with client
- Conduct frequent client communications
- Form project steering committee
- Assign a senior SR executive as QA Executive
- Conduct internal editorial & quality reviews of project deliverables
- Certify project staff in SR methodologies & standards
- Monitor client satisfaction
- Monitor realized value post-project
Case Study- Automotive Sector
One of the key manufacturers of automotive had plans to invest in electric utility vehicles. The electric cars and associated markets being a of evolving nature, the automotive client approached Straits Research for a detailed insight on the market forecasts. The client specifically asked for competitive analysis, regulatory framework, regional prospects studied under the influence of drivers, challenges, opportunities, and pricing in terms of revenue and sales (million units).
Solution
The overall study was executed in three stages, intending to help the client meet its objective of precisely understanding the entire market before deciding on an investment. At first, secondary research was conducted considering political, economic, social, and technological parameters to get a gist of the various aspects of the market. This stage of the study concluded with the derivation of drivers, opportunities, and challenges. It also laid substantial emphasis on understanding and collecting data not only on a global scale but also on the regional and country levels. Data Extraction through Primary Research
The second stage involved primary research in which several market players and automotive parts suppliers were contacted to study their viewpoint concerning the development of their market and production capacity, clientele, and product line. This stage concluded in a brief understanding of the competitive ecosystem and also glanced through the strategies and pricing of the companies profiled.
Market Estimates and Forecast
In the final stage of the study, market forecasts for the electric utility were derived using multiple market engineering approaches. This data helped the client to get an overview of the market and accelerate the process of investment.
Case Study- ICT Sector
Business process outsourcing, being one of the lucrative markets from both supply- and demand- side, has appealed to various companies. One of the prominent corporations based out of Japan approached us with their requirements regarding the scope of the procurement outsourcing market for around 50 countries. Additionally, the client also sought key players operating in the market and their revenue breakdown in terms of region and application.
Business Solution
An exhaustive market study was conducted based on primary and secondary research that involved factors such as labor costs in various countries, skilled and technical labors, manufacturing scenario, and their respective contributions in the global GDP. A comparative study of the market was conducted from both supply- and demand side, with the supply-side comprising of notable companies, such as GEP, Accenture, and others, that provide these services. On the other hand, large manufacturing companies from them demand-side were considered that opt for these services.
Conclusion
The report aided the client in understanding the market trends, including country-level business scenarios, consumer behavior, and trends in 50 countries. The report also provided financial insights of crucial players and detailed market estimations and forecasts till 2028.
}})
Pricing
Select a license type that suits your business needs
Single User Access
US $3950
Only Three Thousand Nine Hundred Fifty US dollar
- 1 User access
- 15% Additional Free Customization
- Free Unlimited post-sale support
- 100% Service Guarantee until achievement of ROI
Multi User Cost
US $4950
Only Four Thousand Nine Hundred Fifty US dollar
- 5 Users access
- 25% Additional Free Customization
- Access Report summaries for Free
- Guaranteed service
- Dedicated Account Manager
- Discount of 20% on next purchase
- Get personalized market brief from Lead Author
- Printing of Report permitted
- Discount of 20% on next purchase
- 100% Service Guarantee until achievement of ROI
Enterprise User Cost
US $5950
Only Five Thousand Nine Hundred Fifty US dollar
- Unlimited User Access
- 30% Additional Free Customization
- Exclusive Previews to latest or upcoming reports
- Discount of 30% on next purchase
- 100% Service Guarantee until achievement of ROI